These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1248 related articles for article (PubMed ID: 27048650)

  • 21. Metabolic control of YAP and TAZ by the mevalonate pathway.
    Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
    Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
    Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway.
    Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X
    Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
    Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
    Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 31. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
    Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
    FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
    Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
    J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of LPA and the Hippo pathway on apoptosis in salivary gland epithelial cells.
    Hwang SM; Jin M; Shin YH; Ki Choi S; Namkoong E; Kim M; Park MY; Park K
    Exp Mol Med; 2014 Dec; 46(12):e125. PubMed ID: 25502757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YAP and TAZ are distinct effectors of corneal myofibroblast transformation.
    Muppala S; Raghunathan VK; Jalilian I; Thomasy S; Murphy CJ
    Exp Eye Res; 2019 Mar; 180():102-109. PubMed ID: 30578787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Hippo Pathway in Prostate Cancer.
    Salem O; Hansen CG
    Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.